Submission to the Patented Medicines Pricing Review Board - Amendments to the interim guidance Re: New medicines

The CLHIA is pleased to provide the views of its members to the Patented Medicines Pricing Review Board (PMPRB) for consideration regarding the draft Interim Guidelines, which define the processes for review of drug pricing for patented drugs approved in Canada. These Interim Guidelines will allow PMPRB to re-start the process of reviewing new patented drugs for maximum price.

PMPRB-Interim Draft Guidelines.pdf